EURORDIS, Platforme Maladies Rares, 96 rue Didot, 75014, Paris, France.
Adv Exp Med Biol. 2010;686:223-50. doi: 10.1007/978-90-481-9485-8_14.
Rare disease patients experience particular obstacles in accessing high quality healthcare. These obstacles include but are not limited to: (i) lack of scientific knowledge of their disease, (ii) lack of access to correct diagnosis, (iii) delays in diagnosis, (iv) lack of appropriate multidisciplinary healthcare, (v) lack of quality information and support at the time of diagnosis, (vi) undue social consequences, (vii) inequities and difficulties in access to treatment, rehabilitation and care, (viii) dissatisfaction with and loss of confidence in medical and social services, (ix) denied treatment by health professionals and (x) lack of availability of orphan drugs. Three surveys and their subsequent analysis, conducted by the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient driven alliance of European patient organisations, demonstrate several of these obstacles by describing the experience of rare disease patients across 18 rare diseases and over 24 European countries as well as highlighting inequalities that exist between them.
罕见病患者在获得高质量医疗保健方面面临特殊障碍。这些障碍包括但不限于:(i)缺乏对其疾病的科学认识,(ii)无法获得正确的诊断,(iii)诊断延误,(iv)缺乏适当的多学科医疗保健,(v)诊断时缺乏质量信息和支持,(vi)社会后果不当,(vii)获得治疗、康复和护理方面的不平等和困难,(viii)对医疗和社会服务的不满和失去信心,(ix)卫生专业人员拒绝治疗,以及(x)孤儿药的缺乏。欧洲罕见病组织(EURORDIS)是一个由欧洲患者组织组成的非政府、以患者为驱动的联盟,该组织进行了三项调查及其后续分析,通过描述 18 种罕见病和 24 个以上欧洲国家的罕见病患者的经历,以及强调它们之间存在的不平等现象,说明了其中的一些障碍。